SynthesisMolecular neurobiology2015
The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis.
Synthesis in Molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Clinicalpathological and prognostic significance of survivin expression in renal cell carcinoma: a meta-analysis.Oncotarget · 2017Pooled it
- Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Expression and Prognostic Significance of p53 in Glioma Patients: A Meta-analysis.Neurochemical research · 2016Pooled it
- The Clinical Implications of Transforming Growth Factor Beta in Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis.Molecular neurobiology · 2015Pooled it
- The construction of a novel prognostic prediction model for glioma based on GWAS-identified prognostic-related risk loci.Open medicine (Warsaw, Poland) · 2024Article
- Scutellarin inhibits the glioma cell proliferation by downregulating BIRC5 to promote cell apoptosis.Journal of cellular and molecular medicine · 2023Article
- Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor GrowthClinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.Oncotarget · 2017Article
- Survivin - The inconvenient IAP.Seminars in cell & developmental biology · 2015Review
- Recent Advances on Small-Molecule Survivin InhibitorsCurrent medicinal chemistry · 2015Article
- Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.Therapeutic delivery · 2015Review
- Downregulation of ring-finger protein 43 in glioma associates with poor prognosis.International journal of clinical and experimental pathology · 2015Article
- Article
Corrections and comments
- Retraction · 2017-04-01Compromised Peer Review · False/Forged Authorship · Plagiarism of Text ·
- Retracted
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to now, survivin has been recommended as a prognostic and diagnostic indicator in glioma patients. However, there are still many controversies. Here, a meta-analysis was conducted to draw a more definitive conclusion on the correlation of survivin with overall survival (OS), age, gender, and WHO grade. Eligible studies were available through careful assessment, and then pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated. Funnel plots were introduced to evaluate the publication bias. Additionally, heterogeneity and sensitivity were also evaluated. In the present meta-analysis, 15 eligible studies with a total of 1,089 patients were incorporated. Survivin expression in gliomas correlated with 2-year OS (n = 8; HR 0.17, 95% CI 0.11-0.26) and 5-year OS (n = 7; HR 0.12, 95% CI 0.07-0.22) in patients. In addition, a fixed-effect model revealed a significant association between survivin and age (male/+; OR 2.10, 95% CI 1.44-3.05) and survivin and WHO grade (I+II/+; OR 0.27, 95% CI 0.19-0.38). No heterogeneity was observed across all studies. According to Begg's and Egger's test and funnel plot, no publication bias was reported. Taken together, our meta-analysis suggests that survivin expression is associated with poor survival, older age, and higher WHO grade and could be suggested as a useful prognostic and diagnostic biomarker, or an effective therapy target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.